Illustration: Sarah Grillo/Axios

President Trump is viewed by many on the left as a tool of big business, thanks largely to the 2017 tax cuts, but when it comes to corporate mergers and acquisitions, he's been more foe than friend.

The big picture: The administration has blocked, sued to block, or threatened to block big deals in a number of industry sectors. Sometimes it's been done on antitrust grounds. Sometimes on national security grounds. Sometimes, it seems, on gussied-up whim.

Why it matters: "Subject to regulatory approval" for decades was an M&A risk factor that merging companies disclosed as boilerplate. Today, however, it's rarely a foregone conclusion — and post-announcement analysis is as much about if a deal will be allowed to close as it is about price, product, financing, layoffs, or strategic coherence.

  • In media, notable examples under Trump include DOJ seeking to block AT&T from buying Time Warner, Sinclair being blocked from buying Tribune Media, and the major divestiture requirements on T-Mobile's deal for Sprint.
  • In healthcare, DaVita, Bristol-Myers Squibb, and CVS each were forced to make significant divestitures in order to gain approval for multi-billion dollar acquisitions.
  • In tech, Broadcom was blocked from buying Qualcomm, Canyon Bridge from buying Lattice Semiconductor, and DraftKings from merging with FanDuel.
  • In printing, Quad/Graphics Inc. and LSC Communications recently abandoned their planned merger due to federal opposition.
  • In defense, Harris Corp. was forced to sell a night vision unit in order to merge with L3 Technologies, and Trump has publicly expressed unease with United Technologies' proposed deal for Raytheon.

Yes, but: Sometimes deals do close, but then are forced by U.S. regulators to be unwound. That's what happening right now with Pamplona Capital Management's 2018 purchase of a 47% stake in cybersecurity company Cofense (f.k.a. PhishMe) and Kunlun's 2016 purchase of dating app Grindr (although U.S. opposition appears to be softening).

  • Speaking of Kunlun, the bar for Chinese takeovers of U.S. companies has been placed so high that they aren't really worth the attempt.

The bottom line: Trump's love of big things and distaste for regulation and judicial "activism" doesn't extend to M&A, where he seems reflexively opposed to big mergers and in favor of stricter rules and "activist" regulators.

Go deeper: One week of the not-normal presidency

Go deeper

Big Tech marshals a right-leaning army of allies for antitrust fight

Illustration: Eniola Odetunde/Axios

As tech's giants prepare to face off with antitrust enforcers this summer, they will draw support from an array of predominantly right-leaning defenders ranging from influential former government officials to well-connected think tanks.

The big picture: The Justice Department, the Federal Trade Commission and the states have multiple investigations of monopolistic behavior underway targeting Facebook and Google, with other giants like Amazon and Apple also facing rising scrutiny. Many observers expect a lawsuit against Google to land this summer.

John Roberts' long game

Illustration: Sarah Grillo/Axios

Supreme Court Chief Justice John Roberts is not the revolutionary that conservative activists want him to be.

He moves slower than they want, sides with liberals more than they want, and trims his sails in ways they find maddening. But he is still deeply and unmistakably conservative, pulling the law to the right — at his own pace and in his own image.

2 hours ago - Health

The U.S.' new default coronavirus strategy: herd immunity

Illustration: Aïda Amer/Axios

By letting the coronavirus surge through the population with only minimal social distancing measures in place, the U.S. has accidentally become the world’s largest experiment in herd immunity.

Why it matters: Letting the virus spread while minimizing human loss is doable, in theory. But it requires very strict protections for vulnerable people, almost none of which the U.S. has established.